실시간
FierceBiotechReplimmune ramps up layoffs to cover 60% of workforce amid ongoing fallout of FDA rejection10x Genomics Blog10x Genomics debuts Atera, a new platform to redefine how biology is measured and understood at AACR 2026 - SelectScienceIlluminaClinical Genomic Market: Growth and Outlook Driven by Illumina, - openPR.comThermo FisherAssessing Thermo Fisher Scientific (TMO) Valuation After New PCR Launch And Data Partnerships - simplywall.stCuriosis Inc.Working capital per share of Curiosis, Inc. – KRX:494120 - TradingViewWatersWaters Corporation Schedules First Quarter 2026 Earnings Conference Call - ChartMillLonza NewsLonza Group AG stock (CH0013841017): Is its biopharma contract focus strong enough to unlock new ups - AD HOC NEWSCellB cell deficiency limits exercise capacity by remodeling liver glutamate metabolismCellA phytoscreen identifies a garlic compound as a deterrent of mating and egg laying in <em>Drosophila</em> and mosquitoesCellp53 safeguards chemical reprogramming of human somatic cells toward pluripotencyCell2'3'-cGAMP-induced membrane shearing promotes broad antiphage immunityCellGut microbiome is associated with recurrence-free survival in patients with resected high-risk melanoma receiving adjuvant immune checkpoint blockade
BioWorld 2026년 4월 1일

US FDA clears Lilly’s oral GLP-1 Foundayo for weight loss

US FDA clears Lilly’s oral GLP-1 Foundayo for weight loss

원문
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.